Amazon

Thursday, July 12, 2018

Endocrinology | canagliflozin | Ertugliflozin | semaglutide

Intensive cholesterol-lowering confers the greatest benefit in diabetics

Individuals with diabetes who have experienced a recent episode of acute coronary syndrome (ACS) derive the greatest reduction in risk of subsequent major adverse cardiac events (MACE) when given a combination of the PCSK9* inhibitor alirocumab and high-intensity statins compared with individuals with prediabetes or normoglycaemia, according to results of the ODYSSEY OUTCOMES** trial.

Study OBSERVEs no increased risk of below-knee amputation with canagliflozin 

The sodium glucose co-transporter 2 (SGLT-2) inhibitor canagliflozin does not appear to increase the risk of below-knee lower extremity amputations over other SGLT2 inhibitors or non-SGLT2 inhibitor antihyperglycaemic agents in patients with type 2 diabetes (T2D), but may reduce the risk of hospitalization for heart failure (HHF), according to findings of the US-based OBSERVE-4D* study.

Pre-existing T2D, CKD increase mortality risk in heart failure

Having both pre-existing type 2 diabetes (T2D) and chronic kidney disease (CKD) appears to raise the risk of all-cause and cardiovascular disease (CVD)-specific mortality in patients with heart failure, according to results of a Singapore study.

Ertugliflozin improves glycaemic outcomes in T2D

The addition of the sodium-glucose cotransporter-2 inhibitor ertugliflozin to metformin improved glycaemic control, body weight, and blood pressure (BP) in patients with inadequately controlled type 2 diabetes (T2D), according to the results of the VERTIS MET* trial presented at ADA 2018.

Artificial pancreas improves glycaemic control, without increased hypoglycemia in T2D

Insulin delivery using an automated close-loop system significantly improves glycaemic control compared with conventional insulin injection among hospitalized patients with type 2 diabetes (T2D) receiving noncritical care, without increasing the risk of hypoglycemia, according to a study presented at ADA 2018.

Oral semaglutide scores in glycaemic control for T2D in PIONEER-1

A novel formulation of the GLP-1* receptor agonist semaglutide in oral form led to clinically meaningful HbA1c reduction and weight loss at 26 weeks in patients with type 2 diabetes (T2D) uncontrolled on diet and exercise, according to the PIONEER-1 trial presented at ADA 2018.


Monday, April 30, 2018

Prolia® (Denosumab) For your patients with glucocorticoid induced osteoporosis

Prolia® (Denosumab) For your patients with glucocorticoid induced osteoporosis 

There is a new indication for Prolia® For your patients with glucocorticoid induced osteoporosis at high risk for fracture. The manufacturing company is excited to share the news that Prolia is now available as a treatment to increase bone mass for the treatment and prevention of glucocorticoid-induced osteoporosis.

Prolia is now indicated as a treatment to increase bone mass in women and men at high risk for fracture:due to sustained systemic glucocorticoid therapy who are starting or have recently started ionq-terrn glucocorticoid therapy.

Prolia is also indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; available osteoporosis therapy. In postmenopausal women nonvertebral and hip fractures. 

Osteoporosis at high risk for fracture, defined as a history of steoporotic fracture, or multiple risk factors for fracture; Ipatients who have failed or are intolerant to other available osteoporosis therapy. 

As a treatment to increase bone mass in men with onmetastatic prostate cancer receiving androgen eprivation therapy AOTJ. who are at high risk for fracture. treatment to increase bone mass in women with nonmetastatic breast cancer receiving adjuvant aromatase inhibitor (AIJ therapy, who have low bone mass and are at high risk for fracture.

BEPREVE (bepotastine besilate ophthalmic solution) ALLERGIC CONJUNCTIVITIS

BEPREVE 1.5%
ASSOCIATED With ALLERGIC CONJUNCTIVITIS
BEPREVE (bepotastine besilate ophthalmic solution) 1 .5% w/v is indicated for the treatment of itching associated with allergic conjunctivitis.
BEPREVE demonstrated a significant reduction in ocular itching at 3 minutes 
For tile treatment of itching associated with allergic conjunctivitis.1 1!73.8% l

Sunday, March 25, 2018

IMFINZI NOW AVAILABLE IN CANADA

AstraZeneca Canada Inc. announced that IMFINZI is now available in canada
This drug is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma. It comes in two strengths
  • Single use vial of 120mg durvalumb/ 2.4ml (50mg/ml) approx cost $1000.00
  • Single use vial of 500mg durvalumb/ 10ml (50mg/ml) approx cost $4000.00

Tuesday, January 30, 2018

MIFEGYMISO (Mifepristone and Misoprostol combination) medication for early termination up to 63 days

Mifegymiso should be prescribed by health professionals with adequate knowledge of medical abortion and/or who have completed a Mifegymiso education program. 
An Education Program is available on the Celopharma website, www.celopharma.com, for physicians, pharmacists, and other health professionals. 
 
The SOGC continues to offer an accredited education training program at a nominal fee for all health professionals. 

Prior to prescribing MIFEGYMISO, health professionals must: 
 
-Ensure that patients have access to emergency medical care in the 14 days following administration of MIFEGYMISO; 
-Schedule follow-up 7 to 14 days after patients take MIFEGYMISO to confirm complete pregnancy termination; 
-Exclude ectopic pregnancy and confirm gestational age by ultrasound; 
-Counsel each patient on the risks and benefits of MIFEGYMISO, including bleeding, infection, and incomplete abortion; 
-Obtain the patient's informed consent to take the drug.

Each patient should be provided with a printed copy of the Mifegymiso Patient Information Card.  
Patient Information Brochures are available for Pharmacist to order by emailing your request to, info@celopharma.com, or download it from the Celopharma website, www.celopharma.com.  
Mifegymiso can be dispensed directly to patients by a pharmacist or a prescribing health professional. Patients should take the medication as directed by their health professional, either at a health facility or at home.